Literature, news and videos pertinent to
The Robert Schlosser
Program for Rare Lung Cancer Mutations
PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
By The ASCO Post Staff
December 10, 2023 - Supplement: ESMO Highlights
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
By The ASCO Post Staff
October 10, 2022 - Supplement: Conference Highlights IASLC 2022
Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)—CMS.gov Centers for Medicare & Medicaid Services
INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT) —ClinicalTrials.gov
The Robert Schlosser Program for Rare Lung Cancer Mutations is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
For more information about this special program, please click on...
We also accept PayPal™
paypal.me/ICANadvocacy
Federal Tax I.D.: EIN 86-0818253